Does acute and persistent metabolic dysregulation in COVID-19 point to novel biomarkers and future therapeutic strategies?

Eur Respir J. 2022 Feb 24;59(2):2102417. doi: 10.1183/13993003.02417-2021. Print 2022 Feb.

Abstract

Metabolomics changes in COVID-19 predict acute patient outcomes and suggest a role for a bioenergetic crisis. Thus, metabolomics changes in COVID-19 may serve as a biomarker and provide insight into pathogenic mechanisms and pharmacologic targets. https://bit.ly/2XkJeU8

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • Biomarkers
  • COVID-19*
  • Graft vs Host Disease*
  • Humans
  • SARS-CoV-2

Substances

  • Biomarkers